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Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have
(borderline) resectable pancreatic cancer [(B)RPC] at diagnosis. Upfront resection
with adjuvant chemotherapy has long been the standard of care for these patients.
However, although surgical quality has improved, still about 50% of patients never
receive adjuvant treatment. Therefore, recent developments have focused on a
neoadjuvant approach. Directly comparing results from neoadjuvant and adjuvant
regimens is challenging due to differences in patient populations that influence outcomes.
Neoadjuvant trials include all patients who have (B)RPC on imaging, while adjuvant-
only trials include patients who underwent a complete resection and recovered to
a good performance status without any evidence of residual disease. Guidelines
recommend neoadjuvant treatment for BRPC patients mainly to improve negative
resection margin (R0) rates. For resectable PDAC, upfront resection is still considered
the standard of care. However, theoretical advantages of neoadjuvant treatment,
including the increased R0 resection rate, early delivery of systemic therapy to all
patients, directly addressing occult metastatic disease, and improved patient selection
for resection, may also apply to these patients. A systematic review by intention-to-treat
showed a superior median overall survival (OS) for any neoadjuvant approach (19
months) compared to upfront surgery (15 months) in (B)RPC patients. A neoadjuvant
approach was recently supported by three randomized controlled trials (RCTs). For
resectable PDAC, neoadjuvant treatment was superior in a Japanese RCT of neoadjuvant
gemcitabine with S-1 vs. upfront surgery, with adjuvant S-1 in both arms (median
OS: 37 vs. 27 months, p = 0.015). A Korean trial of neoadjuvant gemcitabine-based
chemoradiotherapy vs. upfront resection in BRPC patients was terminated early due
to superiority of the neoadjuvant group (median OS: 21 vs. 12 months, p = 0.028;
R0 resection: 52 vs. 26%, p = 0.004). The PREOPANC-1 trial for (B)RPC patients
also showed favorable outcome for neoadjuvant gemcitabine-based chemoradiotherapy
Janssen et al. Neoadjuvant Treatment in Pancreatic Cancer
vs. upfront surgery (median OS: 17 vs. 14 months, p = 0.07; R0 resection: 63 vs. 31%,
p < 0.001). FOLFIRINOX is likely a better neoadjuvant regimen, because of superiority
compared to gemcitabine in both the metastatic and adjuvant setting. Currently, five
RCTs evaluating neoadjuvant modified or fulldose FOLFIRINOX are accruing patients.
Keywords: pancreatic cancer, neoadjuvant, FOLFIRINOX, borderline resectable, pancreatic ductal
adenocarcinoma, resectable, ongoing trials, evidence
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) accounts for 3% of
all new cancer diagnoses, and incidence rates continue to slowly
increase. In contrast to the decreasing cancer-related death rates
for many other solid organ malignancies, PDAC survival has
not shown much improvement over the last decades (1). As a
consequence, PDAC is expected to be the second leading cause
of cancer-related death in the United States by 2030 (2). An
important explanation for the high mortality rate compared to
other solid tumors, is that the majority of patients are diagnosed
with metastatic disease (40%) or locally advanced disease (40%).
For metastatic PDAC, palliative treatment using multi-agent
chemotherapy such as a combination of 5-FU, oxaliplatin, and
irinotecan (FOLFIRINOX) or gemcitabine with nab-paclitaxel
is the standard of care based on randomized controlled trials
(RCTs) (3, 4). These therapies have been shown to increase life
expectancy with 2–4 months. For locally advanced pancreatic
cancer (LAPC), no RCT has been completed, but based on a
patient-level meta-analysis and the survival benefit in metastatic
PDAC, FOLFIRINOX, and gemcitabine with nab-paclitaxel
are the standard initial treatments (5). Following induction
chemotherapy, some patients will also receive chemoradiation
and about 20% of LAPC patients undergoes surgical resection.
The remaining 20% of PDAC patients have (borderline)
resectable pancreatic cancer [(B)RPC] at diagnosis.
Resection remains the only curative-intent treatment.
However, even curative-intent surgery typically does not
overcome the aggressive biology, resulting in recurrent disease
within 2 years after resection in the vast majority of patients
(6). Studies focusing on recurrence patterns have demonstrated
that the initial recurrence in 76% of patients was systemic (7, 8).
Therefore, also (B)RPC could be approached as a systemic
disease, irrespective of apparent non-metastatic disease on
imaging (9).
The objective of this paper is two-fold. First, we aim to
give a general overview of the current treatment strategies for
(B)RPC patients, to discuss the rationale for neoadjuvant and
adjuvant therapy, and to consider the challenges when comparing
these treatment approaches. Second, we aim to summarize the
currently available evidence for neoadjuvant treatment with a
special focus on neoadjuvant FOLFIRINOX, including published
and ongoing phase II-III trials for neoadjuvant treatment.
METHODS
To identify relevant studies for neoadjuvant treatment, a
comprehensive search of Clinicaltrials, Embase, and MEDLINE
was performed. Search terms included “neoadjuvant,”
“FOLFIRINOX,” “folinic acid,” “fluorouracil,” “irinotecan,”
“oxaliplatin,” “pancreas cancer,” “drug combination,” and
relevant variants thereof. Only articles written in English were
assessed. Articles were selected based on relevance for our
objectives, considering methodological quality, study type,
number of included patients, and additional value to current
knowledge. A selection was made for prospective studies with
restriction to phase II and III trials and publication dates from
2006 to 2019. Furthermore, references of included articles were
assessed for additional relevant literature.
Disease Staging
Non-metastatic pancreatic cancer is subdivided into resectable
PDAC, BRPC, and LAPC. Historically however, BRPC was not
recognized as a unique disease stage. In 2001, a first definition
of marginally resectable tumors was proposed (10). The term
“borderline resectable” was thereafter introduced by the 2006
National Comprehensive Cancer Network (NCCN) guidelines
for tumors at risk formargin-positive resection when treated with
upfront surgery, and adopted by other guidelines. The critical
aspects that need to be evaluated are the contact of the tumor
with the superior mesenteric vein or portal vein complex (SMV-
PVC) as venous structures, and the superior mesenteric artery
(SMA), common hepatic artery (CHA), and celiac artery (CA) as
major surrounding arteries. Over time, several criteria have been
proposed to define resectability status, summarized in Table 1.
Commonly used criteria include the NCCN guidelines (15,
16), MD Anderson Cancer Center (MDACC) guidelines (11, 12),
the AHPBA/SSAT/SSO expert consensus guidelines (13), and
the International Study Group of Pancreatic Surgery (ISGPS)
criteria (14). The 2013 NCCN guidelines adopted the ISGPS
criteria, and minor modifications were made in the following
NCCN guidelines. The AHPBA/SSAT/SSO guidelines require
less vascular abutment to classify patients as BRPC compared to
the NCCN and MDACC guidelines. For example, tumors with
any SMV-PVC abutment are BRPC in the AHPBA/SSAT/SSO
guidelines. In contrast, the other two guidelines require venous
occlusion (MDACC) or vein contour irregularity (NCCN),
regardless of the extent of abutment of the tumor with
the SMV-PVC.
Several factors associated with these criteria have complicated
comparison of study outcomes. First, no uniformly accepted
set of criteria exists. Second, the NCCN guidelines have
been modified several times. Third, most guidelines include
ambiguous terms to define the resectability stages, including
“abutment, impingement, involvement, and encasement.” The
classifications are based on apparent contact on imaging
of tumor and blood vessel. The actual presence of tumor
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TABLE 1 | Comparison of imaging-based criteria distinguishing resectable, borderline resectable, and locally advanced pancreatic cancer.
MD Anderson
(2008) (11, 12)*
AHPBA/SSAT/SSO
(2009) (13)
ISGPS
(2014)**(14)
NCCN
(2019)*** (15)
RESECTABLE PANCREATIC CANCER
SMA No contact
CHA
CA
SMV—PVC Patent No abutment, distortion, thrombus,
or encasement
No distortion No contact or ≤180◦ without vein
contour irregularity
BORDERLINE RESECTABLE PANCREATIC CANCER
SMA ≤180◦
CHA ≤180◦ or short-segment encasement
(>180◦) without extension to celiac
axis or hepatic artery bifurcation,
allowing for safe and complete
resection and reconstruction
Encasement of gastroduodenal artery up to CHA with short segment
encasement or direct abutment of CHA without extension to celiac axis
Contact without extension to celiac
axis or hepatic artery bifurcation,
allowing for safe and complete
resection and reconstruction.
CA ≤180◦ No abutment or encasement ≤180◦ or (for corpus) >180◦ without
aortic involvement and intact
gastroduodenal artery permitting
modified Appleby procedure.
SMV—PVC Segmental occlusion with possibility
of reconstruction
Abutment, encasement or
short-segment occlusion with
possibility of reconstruction
Distortion, narrowing, or occlusion
with possibility of reconstruction
>180◦ or ≤180◦ with contour
irregularity or occlusion with
possibility of complete resection and
reconstruction, or solid tumor contact
with inferior vena cava.
LOCALLY ADVANCED PANCREATIC CANCER
SMA >180◦
CHA ≤180◦ or >180◦ with extension to
celiac axis, splenic or left gastric
junction
Encasement of gastroduodenal artery up to CHA with short segment
encasement or direct abutment of CHA with extension to celiac axis
Contact with extension to celiac axis
or hepatic artery bifurcation
CA >180◦ Abutment or encasement and
technically not reconstructable
Abutment, or any contact with aortic
involvement
>180◦ or any contact with aortic
involvement
SMV—PVC Occluded or encased and technically not reconstructable Unreconstructable duo to tumor
involvement or occlusion, or contact
with most promixal draining jejunal
branch into SMV
SMA, superior mesenteric artery; CHA, common hepatic artery; CA, celiac artery; SMV—PVC, superior mesenteric vein—portal vein complex; AHPBA/SSAT/SSO, Americas Hepato-
Pancreato-Biliary Association/Society of Surgical Oncology/Society for Surgery of the Alimentary Tract; NCCN, National Comprehensive Cancer Network.*Patients with poor functional
status and/or severe medical comorbidities (type C), as well as those with technically resectable disease but with imaging studies suspicious for metastatic disease (type B) are also
classified as borderline resectable. **The ISGPS criteria were adopted by the 2013 NCCN criteria. ***The NCCN criteria have changed over the years. The most recent criteria (3.2019)
are included.
cells surrounding the vessels (or invading the vessel wall) is
rarely known before pathological examination of the resected
specimen. However, patients with extensive apparent contact on
imaging often undergo a surgically incomplete (R1) resection,
suggesting imaging is indeed a good predictor of the presence
of tumor cells surrounding and/or invading the vessel wall.
Lack of international agreement on the definition of an R0
resection (i.e., >1 vs. >0mm) and standardized protocols for
pathological examination (i.e., axial slicing vs. bivalving) may
explain variation in published R0 resection rates (17, 18). At
a consensus meeting in 2016, it has been proposed to add
biological and functional risk factors to the resectability criteria.
Biological factors include elevated Carbohydrate Antigen (CA)
19.9 levels above 500 units/mL, regional lymph node metastases,
and suspicion of distant metastases without the possibility for
pathological proof. The functional factors include performance
status and comorbidity (19). These biological and functional
factors have also been implemented in the NCCN 2018 and
American Society of Clinical Oncology (ASCO) 2019 guidelines,
further decreasing the number of patients classified as resectable
PDAC (20, 21). Similarly, within the MDACC guidelines, three
sub-types of BRPC are distinguished; based on local tumor-
artery contact (type A), based on tumor marker levels or imaging
suggestive of metastatic disease but lacking pathological proof
(type B), or based on marginal performance status prior to
treatment (type C) (11, 12).
Adjuvant Treatment—Practice Changing
Trials
Upfront surgery followed by adjuvant chemotherapy has long
been the standard of care for patients with potentially resectable
PDAC. Initial adjuvant treatment strategies included both
chemotherapy and radiotherapy. In 2004, the long-term results
from the ESPAC-1 (European Study Group for Pancreatic
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Cancer) trial were published (22). This multicenter European
collaboration used a 2 × 2 factorial design to compare adjuvant
5-FU-based chemoradiotherapy alone (arm A, n = 73), adjuvant
5-FU based chemoradiotherapy followed by 5-FU (arm B,
n = 72), adjuvant 5-FU alone (arm C, n = 75), and observation
alone (arm D, n = 69). The trial was not powered for a
direct comparison of the four groups, yet survival was longer
in patients who received chemotherapy compared to patients
who did not [median OS: 20 vs. 16 months, hazard ratio
(HR) 0.71, p = 0.009]. Furthermore, comparison of patients
with or without chemoradiotherapy showed inferior median
OS for patients who received chemoradiotherapy (median OS:
16 vs. 18 months, HR 1.28, 95% CI: 0.99–1.66, p = 0.05).
The CONKO-001 (Charité Onkologie 001) trial found that
adjuvant gemcitabine was superior to observation alone with
a 5-year survival rate of 21 vs. 10% (p = 0.01) (6). In 2017,
the ESPAC-4 trial included 730 patients comparing gemcitabine
(n = 366) to gemcitabine plus capecitabine (n = 364) (23).
Median OS was 26 months with gemcitabine alone and 28
months with gemcitabine plus capecitabine (HR 0.82, 95% CI:
0.68–0.98, p = 0.032). In 2018, the results of the PRODIGE
24/CCTGPA.6 trial comparing adjuvant gemcitabine tomodified
FOLFIRINOX (mFOLFIRINOX) exceeded expectations (24).
The median OS was 54 months with mFOLFIRINOX compared
to 35 months with gemcitabine (stratified HR 0.64, 95% CI: 0.48–
0.86, p = 0.003). mFOLFIRINOX is currently the best adjuvant
treatment for patients with a good performance score.
Neoadjuvant Treatment—Rationale
The strategy of chemotherapy following surgery has several
drawbacks. First, approximately 20% of patients with (B)RPC
on imaging will never undergo a resection because of occult
metastatic or locally irresectable disease (25). More advanced
disease is often diagnosed at exploratory laparotomy, which
has considerable morbidity and mortality, and the majority
of these patients will not receive any palliative chemotherapy.
Even after successful resection, only about 55% of patients are
able to receive adjuvant chemotherapy due to postoperative
complications, clinical deterioration, or early progressive disease
(26–29). Especially those patients not able to receive adjuvant
chemotherapy have very poor prognosis. The CONKO-001 RCT
reported that about 50% of patients in the observation arm
(i.e., without adjuvant chemotherapy) hadrecurrent disease or
died within 6 months after surgery; the median DFS was only
6.7 months after surgery without adjuvant chemotherapy (6).
In an attempt to overcome some of these drawbacks, there
is an ongoing paradigm shift toward a neoadjuvant approach.
This is supported by promising results in other malignancies
such as breast cancer, rectal cancer, and esophagogastric cancer
(30–32). Theoretical advantages of a neoadjuvant approach
are numerous. First, a much larger population can benefit
from effective systemic treatment. Second, neoadjuvant systemic
therapy directly addresses radiographically occult metastatic
disease. Third, delaying surgery during neoadjuvant treatment
allows for restaging prior to surgery. This provides improved
patient selection by identifying those individuals who have
responded to neoadjuvant treatment and may benefit from a
resection, whilst preventing futile surgery in patients with rapidly
progressive disease. Furthermore, several studies have shown
that complication rates, including postoperative pancreatic
fistula and postpancreatectomy hemorrhage, are lower following
neoadjuvant treatment (33–36). Lastly, neoadjuvant treatment
may reduce tumor volume, with increased likelihood of a margin
negative (R0) resection (25, 37).
Conversely, the neoadjuvant approach has some potential
drawbacks. First, patients might have progressive disease during
neoadjuvant treatment, precluding curative-intent resection.
However, it is unlikely that patients with progressive disease
during chemotherapy would have been cured with upfront
resection, since cure is exceedingly rare with a 10-year OS
of only 4% after surgery (38). Furthermore, since patients
with progression during neoadjuvant treatment do not seem to
respond to chemotherapy, it is likely that these patients would
not have responded to adjuvant chemotherapy either, increasing
their risk of early recurrent or metastatic disease following
surgery. Thus, rather than a missed opportunity of cure, it is
more likely that these patients have been spared futile surgery.
Another potential drawback is the risk of deterioration during
neoadjuvant treatment. Chemotherapy may reduce the patients’
performance status and quality of life because of toxicities.
More specifically, FOLFIRINOX is known for its gastrointestinal
complications, increased risk of infections, fatigue, and sensory
peripheral neuropathy (24). Fortunately, it is rare that patients
become unfit for surgery due to chemotherapy, and no deaths
have been attributed to FOLFIRINOX in two systematic reviews
(5, 39). A final potential drawback is that biliary drainage
is required before chemotherapy in patients with obstructive
jaundice. Biliary drainage is associated with mainly infectious
complications (40), but this can be avoided with upfront surgery.
Comparing Adjuvant With Neoadjuvant
Trials
The PRODIGE 24/CCTG PA.6 trial showed a median survival
of almost 5 years for patients with resectable PDAC treated
with upfront resection and adjuvant mFOLFIRINOX: a survival
estimate far superior than previously reported for other
treatments (24). However, these results apply only to a highly
selected subset of patients. Only patients with favorable tumor
biology and good performance status after a complete curative-
intent resection are eligible for adjuvant trials. Several hurdles
need to be taken by patients with resectable PDAC on imaging.
A small percentage of patients become unfit for surgery in the
preoperative phase due to stent-related complications causing
clinical deterioration. In the operative phase, a resection is not
performed in about 20% of patients who are found to have occult
metastatic or locally irresectable disease. Next, patients need
to recover sufficiently within 12 weeks after surgery to receive
adjuvant chemotherapy. In large cohorts, only about 50% of
patients received adjuvant gemcitabine after a complete resection
(26–29). For adjuvant mFOLFIRINOX, patients need to have
an even better World Health Organization (WHO) performance
status of 0 or 1. Lastly, for the PRODIGE 24/CCTG PA.6 trial,
patients were ineligible if the CA 19.9 level was above 180
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U/mL before start of chemotherapy or in the event of early
postoperative disease recurrence on imaging. We estimate that
on a nationwide level only about 25% of patients with (B)RPC
on imaging could become eligible for adjuvant mFOLFIRINOX.
This also explains the low accrual rate of the PRODIGE 24/CCTG
PA.6 trial of only 1–2 patients on average per center per year.
Patients do not need to overcome most of these hurdles for
inclusion in a neoadjuvant trial. Most patients presenting in
the clinic with (B)RPC on imaging are eligible for neoadjuvant
trials after adequate biliary drainage. Thus, direct comparison of
outcomes of neoadjuvant and adjuvant trials is biased, because
neoadjuvant trials can include almost all patients whilst for
adjuvant trials only the 25% of patients with the best tumor
biology and performance status can be included.
Neoadjuvant Treatment—Systematic
Reviews and Meta-Analyses
One of the first studies describing neoadjuvant treatment for
pancreatic cancer was published in 1980 (41). Over time, different
single-agent or multi-agent chemotherapy regimens were used,
including 5-FU, gemcitabine, mitomycin C, and platinum
compounds. Three large meta-analyses have been published
for non-metastatic PDAC patients describing outcomes after
preoperative treatment (irrespective of the regimen used)
compared to upfront surgery (Table 2) (25, 37, 42). The first
meta-analysis by Gillen et al. included 111 studies published from
1980 to 2009. Chemotherapy regimens were mainly gemcitabine
or 5-FU based, and 94% of studies used chemoradiotherapy
(42). This meta-analysis showed that 33% of patients initially
staged as unresectable pancreatic cancer (BRPC and LAPC)
were able to undergo a resection after preoperative treatment.
Furthermore, estimated survival following resection and R0
resection rates for patients with initially unresectable PDAC
were comparable to patients with resectable PDAC (Median
OS: 23 vs. 21 months; R0 resection: 82 vs. 79%). A second
meta-analysis by Dhir et al. provided an update of the literature
published since 2009, which marks the endorsement of the
AHPBA/SSAT/SSO consensus criteria, as well as the introduction
of newer preoperative regimens (37). In this meta-analysis of
96 studies, the median OS after neoadjuvant treatment for
resectable PDAC and BRPC was similar (18 vs. 19 months).
Furthermore, the R0 resection rate of 85% was much higher
than previously reported in the setting of upfront resection.
The third meta-analysis by Versteijne et al. included only
studies that did not exclude patients who didn’t undergo
resection after neoadjuvant treatment or patients who didn’t
undergo adjuvant chemotherapy after resection (25). These
criteria allowed for intention-to-treat analysis of the survival
outcomes. Reporting by intention-to-treat reflects actual clinical
practice and outcomes, because it allows for non-compliance and
protocol deviations, increasing the generalizability of the results
(43). This reduces potential bias of the treatment effect, because
the study population is not limited to patients that received
planned treatment such as surgery or adjuvant chemotherapy.
Without the intention-to-treat analysis, a selection of patients
with better outcomes due to immortal time bias is likely to occur
(44). This meta-analysis of 38 studies comprising 3843 (B)RPC
patients found superior survival following any neoadjuvant
treatment compared to upfront resection (weighted median
OS: 19 vs. 15 months). Only a negligible number of patients
received neoadjuvant FOLFIRINOX. The resection rate was
higher with upfront surgery (66 vs. 81%, p < 0.001), but the R0
resection rate was better after neoadjuvant treatment (87 vs. 67%,
p < 0.001).
Following the ACCORD-11/PRODIGE-4 trial for metastatic
PDAC by Conroy et al. in 2011, FOLFIRINOX emerged as a
potential preoperative treatment for non-metastatic PDAC (3).
No RCT has been performed for neoadjuvant FOLFIRINOX
in the setting of (B)RPC. The best available estimate for the
outcomes of patients treated with neoadjuvant FOLFIRINOX
comes from a patient-level meta-analysis by Janssen et al. that
included 283 BRPC patients and showed a median OS of 22.2
TABLE 2 | Meta-analyses on neoadjuvant treatment for (borderline) resectable pancreatic cancer.
References No.
studies
No.
patients
No. (B)RPC Treatment Stage(s) OS in months
(95% CI)
Resection %
(95% CI)
R0 resection %
(of resected) (95% CI)
Gillen et al.
(2010) (42)
111 4,394 NR Any preoperative
treatment*
Resectable 23 (12–54)′
8 (6–14)′′
74 (66–81) 82 (73–90)
BRPC/LAPC 21 (9–62)′
10 (6–21)′′
33 (26–41) 79 (72–85)
Dhir et al.
(2017) (37)
96 5,520 2193 Any preoperative
treatment**
Resectable 18 (13–28) 76 (68–84) 88 (80–94)
BRPC 19 (9–45) 69 (59–78) 84 (67–96)
Versteijne et
al. (2018) (25)
38 3,484 1738 Any neoadjuvant
treatment***
Resectable 18 (10–50) 67 (64–70) 85 (NR)
BRPC 19 (11–32) 65 (62–68) 89 (NR)
Janssen et al.
(2019) (39)
20 283 283 FOLFIRINOX ±
(chemo)radiotherapy
BRPC 22 (19–26)′′′ 68 (60–75) 84 (77–89)
No., number; (B)RPC, (borderline) resectable pancreatic cancer; BRPC, borderline resectable pancreatic cancer; CI, confidence interval; LAPC, locally advanced pancreatic cancer; OS,
Overall Survival. *Neoadjuvant chemotherapy in 96% of studies, main agents gemcitabine, 5-FU, mitomycin C, and platinum compounds. Neoadjuvant radiotherapy in 94% of studies
with doses ranging 24–63Gy. **Main chemotherapy agents FOLFIRINOX (810 patients), gemcitabine/taxane/capecitabine (410 patients), other three-drug regimens (60 patients), two-
drug regimens (1,112 patients), single drug gemcitabine/5-FU/capecitabine (1,521 patients). ***All studies used at least chemotherapy as neoadjuvant treatment, including gemcitabine
in 26 of 35 studies. Radiotherapy was given in 29 of 35 studies. No study used radiotherapy as sole neoadjuvant treatment. ′Resected. ′′Not-resected.′′′Based on patient-level data.
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months (39). The pooled resection rate was 68%, with an R0
resection rate of 84%.
Neoadjuvant Treatment—Large
Retrospective Series
In addition to these meta-analyses, two large retrospective
studies investigated the neoadjuvant approach (45, 46). The
largest retrospective study used data from the National Cancer
Database (NCDB) including patients with clinical stage I and
II resected PDAC (45). A propensity score matched analysis
was conducted comparing outcomes for patients who received
neoadjuvant treatment before resection (n = 2005) to patients
who underwent upfront resection (n = 6015). The neoadjuvant
patients had a longer median OS compared to patients who
underwent upfront resection (26 vs. 21 months, adjusted HR
0.72, 95% CI: 0.68–0.78, p < 0.01). Moreover, compared with
a subgroup of patients who received adjuvant therapy after
upfront resection, the neoadjuvant group still had better survival
(26 vs. 23 months, adjusted HR 0.83, 95% CI: 0.73–0.89, p <
0.01). Second, a large observational cohort study from Verona
Hospital included all consecutive BRPC (n = 267) and LAPC
(n = 413) patients (46). Of all patients with newly diagnosed
BRPC or LAPC, 7% received only supportive care owing to
clinical deterioration. FOLFIRINOX (46%) and gemcitabine with
nab-paclitaxel (22%) were the most commonly used regimens,
and additional radiotherapy was applied in 23% of patients.
Resection rate was 24% for BRPC patients, with an R0 resection
rate of 58% for all patients combined. No differences were found
in R0 resection rates between BRPC and LAPC patients and
chemotherapy regimens used.
Published Neoadjuvant FOLFIRINOX Trials
(Phase II and III)
Three non-randomized small (<50 patients) phase II studies
on neoadjuvant FOLFIRINOX for (B)RPC have been published
to date (Table 3A) (47–49). In 2016, the first prospective
multicenter trial was published (ALLIANCE A021101),
including 22 BRPC patients who received preoperative
mFOLFIRINOX (4 cycles) followed by capecitabine-based
chemoradiotherapy (50.4Gy in 28 fractions) (47). This study
demonstrated the feasibility of recruiting patients in a multi-
institutional neoadjuvant FOLFIRINOX study. Fifteen patients
(68%) completed the neoadjuvant treatment and underwent a
resection, with an R0 resection rate of 93%. The median OS was
22 months. In 2018, a similar study was published to determine
the tolerability and efficacy of four cycles of mFOLFIRINOX
both pre- and post-operative in resectable PDAC (48). Twenty-
one patients were included, of whom 81% underwent a resection
with an R0 resection rate of 94%. Following resection, 82% of
patients completed 4 cycles of adjuvant mFOLFIRINOX. The
largest study was a single-arm phase II clinical trial conducted at
the Massachusetts General Hospital (49). In this study, 48 BRPC
patients were treated with 8 cycles of neoadjuvant FOLFIRINOX
followed by individualized chemoradiotherapy. In patients
with resolution of vascular involvement, FOLFIRINOX was
followed by short-course capecitabine-based chemoradiotherapy
(25Gy in 5 fractions), whilst patients with persistent vascular
involvement were treated with long-course chemoradiotherapy
(50.4 0Gy in 28 fractions). Forty-four patients (92%) proceeded
to chemoradiotherapy, of whom 27 (56%) received short-
course chemoradiotherapy and 17 (35%) received long-course
chemoradiotherapy. Surgical resection was performed in 32
(67%) patients, of whom 31 (97%) had an R0 resection. After a
median follow-up of 18 months, median OS was 38 months, with
a 2-year OS of 56% (NCT0591733).
Although, the three studies slightly differ in the treatment
regimen and sequence, neoadjuvant (m)FOLFIRINOX treatment
with or without chemoradiotherapy is feasible with high R0
resection rates. The survival estimates are promising, but need
confirmation in larger RCT’s.
Published Neoadjuvant Trials—Regimens
Other Than FOLFIRINOX (Phase II and III)
A number of phase II–III trials have been conducted using other
neoadjuvant regimens, yet several of these RCTs were terminated
early due to slow accrual. This emphasizes the difficulties
in conducting large neoadjuvant RCTs in pancreatic cancer.
Table 3B shows eight published studies on neoadjuvant regimens
other than FOLFIRINOX. Three RCTs have been published on
neoadjuvant gemcitabine-based chemoradiotherapy vs. upfront
surgery for patients with (B)RPC (50, 52, 53). The study
by Golcher et al. was terminated early due to slow accrual
after inclusion of 73 (29%) patients (50). They concluded that
neoadjuvant chemoradiation is safe with respect to toxicity,
postioperative morbidity, and mortality, but no difference in
OS could be demonstrated (median OS: 17 vs. 14 months,
p = 0.96). In the Korean randomized phase II-III trial, BRPC
patients were randomly assigned to receive gemcitabine-based
chemoradiotherapy (45Gy in 25 fractions and 9Gy in 5 fractions)
(arm A) or upfront surgery followed by chemoradiotherapy
following the same protocol as the neoadjuvant group (arm
B) (52). Both groups received 4 cycles of gemcitabine as
maintenance chemotherapy after completion of initial treatment.
After inclusion of 50 patients, interim-analysis showed superior
median OS (21 vs. 12 months, HR = 1.97, 95% CI: 1.07–
3.62, p = 0.028), better 2-year survival rate (41 vs. 26%), and
a superior R0 resection rate (52 vs. 26%, p = 0.004) in the
neoadjuvant group compared to upfront surgery. Consequently,
the study was discontinued due to superiority and lack of
equipoise (NCT01458717). At ASCO 2018, the Dutch phase
III PREOPANC-1 trial presented preliminary results, after
inclusion of 246 (B)RPC patients who were randomly allocated
to neoadjuvant gemcitabine-based chemoradiotherapy followed
by a resection and adjuvant 4 cycles of gemcitabine (arm A), or
upfront surgery followed by 6 cycles of gemcitabine (arm B) (53).
After 85% of events needed, the interim analysis showed superior
R0 resection rate (63 vs. 31%, p< 0.001) and superior DFS (10 vs.
8 months, p= 0.02) in the neoadjuvant group, but a difference in
OS could not be demonstrated (17 vs. 14 months, HR = 0.74,
p = 0.07). To allow for comparison with adjuvant trials, a
subgroup analysis was performed of patients who received at
least one cycle of adjuvant chemotherapy, showing a median
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TABLE 3 | Recently published neoadjuvant trials in (borderline) resectable pancreatic cancer from 2016 to 2019.
Trial (year) Sample
size
Stage Criteria Treatment regimen
(cycles)
Comparator
(cycles)
Survival (p–value) Resection
(p–value)
R0 resection
(p–value)
A. NEOADJUVANT FOLFIRINOX
Non-randomized studies
ALLIANCE
A021101 (2016)
(47)
22 BRPC Intergroup Neoadj.
mFOLFIRINOX(4) +
capecitabine-based
CRT
– Median OS: 22 mo 68% 93%′
De Marsh et al.
(2018) (48)
21 Resectable NCCN Periop.
mFOLFIRINOX(4+4)
– Median OS: 36 mo
(resected only)
81% 94%′′
Murphy et al.
(2018) (49)
48 BRPC NR Neoadj.
FOLFIRINOX(8) +
short-course or
long-course
capecitabine-based
CRT
– Median OS: 38 mo 67% 97%′
B. NEOADJUVANT REGIMENS OTHER THAN FOLFIRINOX
Randomized trials
Golcher et al.
(2015) (50)
73* Resectable <180◦ arterial or
venous contact
Neoadj.
gemcitabine+cisplatin
based CRT + adj.
gemcitabine(6)
Surgery + adj.
gemcitabine(6)
Median OS: 17 vs. 14
mo (p = 0.96)*
58 vs. 70%
(p = 0.31)*
89 vs. 70%
(p = 0.81)*nr
PACT-15 (2018)
(51)
93 Resectable No vascular
contact
c. Periop. PEXG(3+3) a. Surgery +
adj.
gemcitabine(6)
b. Surgery +
adj. PEXG(6)
Median OS: 38 (c) vs.
20 (a) vs. 26 (b) mo
(NR)
1-YR DFS: 66% (c)
vs. 23% (a) vs. 50%
(b) (NR)
84 (c) vs.
85 (a) vs.
90% (b)
(NR)
63 (c) vs.
27 (a) vs. 37%
(b) (NR)nr
Jang et al.
(2018) (52)
50 BRPC NCCN Neoadj.
gemcitabine-based
CRT + adj.
gemcitabine(4)
Surgery + adj.
gemcitabine-
based CRT+
gemcitabine(4)
Median OS: 21 vs. 12
mo (p = 0.028)
2-YR OS: 41 vs. 26%
63 vs. 78%
(NR)
52 vs. 26%
(p = 0.004)′′′
PREOPANC-1
(2018) (53)
246 (B)RPC DPCG Neoadj.
gemcitabine-based
CRT(3) + adj.
gemcitabine(4)
Surgery + adj.
gemcitabine(6)
Median OS: 17 vs. 14
mo** (p = 0.07)
Median DFS: 10 vs. 8
mo** (p = 0.02)
60 vs. 72%**
(p = 0.065)
63 vs. 31%**
(p<0.001)′′′
Preop-02/JSAP-
05 (2019)
(54)
364 Resectable NR Neoadj. S-1 +
gemcitabine(2) + adj.
S-1(6 mo)
Surgery + adj.
S-1(6 mo)
Median OS: 37 vs. 27
mo (p = 0.015)
NR*** NR***nr
Non-randomized studies
Tsai et al. (2018)
(55)
130 (B)RPC <180◦ SMA or
CA, short segment
abutment HA,
venous
reconstructable
Neoadj. 5-FU- or
gemcitabine-based
chemo(radio)therapy
(8w), depending on
molecular profiling
– Median OS: 38 mo
80% 5-FU-based
20% gemcitabine-
based
82% 81%′′
ACOSOG Z5041
(2018) (56)
114 Resectable No arterial
contact, <180◦
venous contact,
no occlusion
Periop. gemcitabine +
erlotinib (2+2)
– Median OS: 21 mo
2-YR OS: 40%
73% 81%nr
JASPAC-05
(2019) (57)
52 BRPC <180◦ SMA, CHA,
or CA. Bilateral
impingement of
SMV/PV.
Neoadj. S1-based
CRT
– Median OS: 26 mo
2-YR OS: 51%
NR** 52%nr
FOLFIRINOX, folinic acid + irinotecan + oxaliplatin + leucovorin; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; NCCN, National
Comprehensive Cancer Network; DPCG, Dutch Pancreatic Cancer Group; NR, not reported; DFS, disease free survival; OS, overall survival; Neoadj., neoadjuvant; Adj., adjuvant;
Periop., perioperative; CRT, chemoradiotherapy; mo, months; d, days; PEXG, cisplatin, epirubicin, gemcitabine, and capecitabine; YR, year; YRS, year survival; SMA, superior mesenteric
artery; CHA, common hepatic artery; CA, celiac artery; SMV, superior mesenteric vein; PV, portal vein. *Results after early termination of the trial due to slow accrual. **Results at interim
analysis, after 85% of events needed. ***Not reported in abstract, paper not yet published. ′R1 if microscopic tumor at any margin. ′′R1 if microscopic tumor at SMA margin, common
bile/hepatic duct or pancreatic transaction margins. ′′′R1 if microscopic tumor <1mm of any surface or margin. nrdefinition of resection margin not reported.
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OS of 42 months in the neoadjuvant group and 19 months in
the upfront surgery group (p = 0.006). Final results are awaited
soon. The PACT-15 trial was an Italian multicenter phase II trial,
in which 93 resectable PDAC patients were randomly assigned
(1:1:1) to receive adjuvant gemcitabine (arm A), adjuvant PEXG
(cisplatin, epirubicin, gemcitabine, and capecitabine) (arm B),
or 3 cycles of PEXG pre- and postoperative (arm C) (51).
Median OS was 20 months in arm A, 26 months in arm B,
and 38 months in arm C (p-value not reported). Three non-
randomized studies on regimens other than FOLFIRINOX have
been published (55–57). The phase II trial from Tsai et al. used
molecular profiling of pretreatment EUS-FNA guided tumor
biopsies using 6 biomarkers to guide neoadjuvant therapy in
130 (B)RPC patients (55). Eighty percent of patients received
5-FU based treatment whilst 20% received gemcitabine-based
treatment. The median OS was 38 months, with a 5-year survival
of 34%, a resection rate of 82%, and an R0 resection rate of
81%. The ACOSOG Z5401 single-arm phase II trial was a study
of neoadjuvant gemcitabine plus erlotinib for resectable PDAC.
(56) This study demonstrated a favorable 2-year OS for 114
evaluable patients of 40% (95% CI: 31–49%), with a median
OS of 21 months. At the 2019 ASCO congress, final results of
two Japanese trial were presented. The JASPAC-05 study was
a multicenter, single-arm, phase II of neoadjuvant S-1 based
chemoradiotherapy (57). Fifty-two BRPC patients were included,
and 50 (96%) patients completed the neoadjuvant treatment. The
2-year OS was 51%, with a median OS of 26 months, and an R0
resection rate of 52%. The phase II-III Preop-02/JSAP-05 trial was
a large collaboration study of 57 centers in which 364 patients
with resectable PDAC were randomized to either neoadjuvant
gemcitabine and S-1 chemotherapy (2 cycles) or upfront surgery,
both followed by 6 months of adjuvant S-1 (54). This study also
showed superior survival following neoadjuvant treatment, with
a median OS of 37 vs. 27 months (HR= 0.72, 95% CI: 0.55–0.94,
p = 0.015). No differences were found regarding the resection
rate, R0 resection rate, and postoperative morbidity. Although
S-1 is only used as standard-of-care in East Asia, the study
does provide additional proof of the superiority of neoadjuvant
therapy over upfront resection for patients with resectable PDAC.
In summary, although based on only three RCTs, a
neoadjuvant approach seems to be consistently superior to
upfront resection for R0 resection rates, at least equal or superior
for DFS, and at least equal or superior for OS in both BRPC and
resectable PDAC patients. The results of the R0 resection rates
were notable, with a two-fold increase in two out of the three
evaluable RCTs. However, it remains unclear whether superior
R0 resection rate is an appropriate intermediate outcome for OS
in the neoadjuvant setting. The results of ongoing larger RCTs
may further clarify the survival benefit of neoadjuvant treatment
as opposed to upfront resection for (B)RPC patients.
Standard of Care—Current Guidelines
The NCCN guideline, ASCO Clinical Practice Guideline, and
European Society for Medical Oncology (ESMO) Clinical
Practice Guideline are commonly used guidelines for pancreatic
cancer treatment (15, 21, 58, 59). Due to the lack of large RCTs
for neoadjuvant treatment of PDAC, most recommendations
in these guidelines are based on systematic reviews of cohort
studies, providing Oxford Levels of Evidence category 2A (60).
The 2019 NCCN guidelines (15) recommend upfront surgery
followed by adjuvant treatment for resectable PDAC, but advise
to consider neoadjuvant treatment in patients with high-risk
features, preferably in the setting of a clinical trial. High-risk
features include imaging findings suspicious of advanced or
metastatic disease, significantly elevated Carcinogen Antigen
(CA) 19-9, large primary tumors or regional lymph nodes,
excessive weight loss, and notable pain. The adjuvant treatment of
first choice is mFOLFIRINOX. For BRPC patients, neoadjuvant
treatment is recommended, with therapeutic options including
FOLFIRINOX or gemcitabine/nab-paclitaxel, both with or
without subsequent chemoradiotherapy. The 2019 ASCO
Clinical Practice Guideline (21) recommends primary surgical
resection for patients without any radiographic evidence of
metastatic disease, with no interface between the primary
tumor and surrounding mesenteric vasculature, CA 19.9 level
suggestive of potentially curable disease, and a performance
status and comorbidity profile appropriate for major abdominal
surgery. However, neoadjuvant therapy can also be offered
as an alternative strategy for patients with resectable PDAC.
For patients who do not meet all of these criteria, the
ASCO guideline recommends neoadjuvant therapy. No specific
neoadjuvant treatment regimen is recommended. Options
for consideration include FOLFIRINOX or gemcitabine/nab-
paclitaxel ± subsequent chemoradiotherapy. In the adjuvant
setting, mFOLFIRINOX is recommended as treatment of first
choice. In case of concern for toxicity and tolerance, doublet
therapy with gemcitabine and capecitabine, or monotherapy
with either gemcitabine or fluorouracil (5-FU) can be offered.
Following neoadjuvant therapy, patients may be candidates
for additional chemotherapy following surgery, depending
on their performance status and initial response to the
neoadjuvant treatment. The ASCO guideline recommends a total
of 6 months of chemotherapy, considering both neoadjuvant
and adjuvant treatment. Adjuvant chemoradiotherapy may be
offered to patients who underwent primary resection with
microscopically positive margins (R1) and/or node-positive
disease after completion of systemic adjuvant chemotherapy.
The 2019 ESMO guideline (58, 59) recommends adjuvant
mFOLFIRINOX as first therapeutic option in selected and
fit individuals with resectable tumors. For patients with age
>70 years, WHO performance status 2, or patients who
have any contraindication for FOLFIRINOX, doublet therapy
with gemcitabine-capecitabine can be offered as alternative.
Gemcitabine monotherapy should be used only in frail patients.
For BRPC patients, neoadjuvant treatment with gemcitabine
or FOLFIRINOX followed by chemoradiotherapy and surgery
is recommended.
Ongoing Neoadjuvant FOLFIRINOX Trials
(Phase II and III)
The optimal chemotherapy regimen in the neoadjuvant setting,
the number of cycles pre- and postoperatively, the additional
benefit of (chemo)radiotherapy, and the timing of surgery after
neoadjuvant treatment still need to be further investigated.
Several ongoing phase II and III trials are investigating these
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TABLE 4 | Ongoing neoadjuvant trials for (borderline) resectable pancreatic cancer.
Trial Sample
size
Stage Criteria Treatment regimen
(cycles)
Comparator
(cycles)
Primary
outcome
Start Status**
A. NEOADJUVANT FOLFIRINOX
Randomized trials
ESPAC-5F
ISRCTN89500674
85 BRPC NR a. Neoadj. FOLFIRINOX(4)
b. Neoadj. gemcitabine(1)+
capecitabine(2)
c. Neoadj.
capecitabine-
based CRT
d. Surgery + adj.
gemcitabine(6)
or 5-FU(6)
Recruitment, R0
resection rate
04-2014 Results
pending
NEPAFOX
NCT02172976
40 (B)RPC Venous
reconstructable, no
contact SMA or CA
Periop. FOLFIRINOX (4-6 +
4-6)
Surgery + adj.
gemcitabine(6)
OS 11-2014 Results
pending
SWOG S1505
NCT02562716
112 Resectable <180◦ venous,
no arterial
Periop. mFOLFIRINOX (3 +
3)
Periop.
gemcitabine/nab-
paclitaxel (3 +
3)
OS at 2-yr 10-2015 Results
pending
NorPACT-1
NCT02919787
90 Resectable NCCN Neoadj. FOLFIRINOX(4) +
adj.
gemcitabine-capecitabine(4)
Surgery + adj.
gemcitabine-
capecitabine(6)
OS at 1-yr
(resected only)
09-2016 Recruiting
PANDAS- PRODIGE 44
NCT02676349
90 BRPC NCCN Neoadj. mFOLFIRINOX +
capecitabine-based CRT +
adj. gemcitabine or mLV5FU
Neoadj.
mFOLFIRINOX +
adj. gemcitabine or
mLV5FU
R0 resection rate 10-2016 Recruiting
ALLIANCE A021501
NCT02839343
134 BRPC Intergroup Neoadj. FOLFIRINOX(8) +
adj. mFOLFOX6(4)
Neoadj.
mFOLFIRINOX(7) +
SBRT + adj.
FOLFOX(4)
OS at 1.5-yr 12-2016 Suspended
(interim
analysis)
PANACHE01-
PRODIGE48
NCT02959879
160 Resectable NCCN a. Neoadj. mFOLFIRINOX(4)
+ adj chemotherapy(8)
b. Neoadj. FOLFOX(4) +
adj. chemotherapy(8)
c. Surgery + adj.
chemotherapy(12)
OS at 1-yr 03-2017 Recruiting
PREOPANC-2
NTR7292
368 (B)RPC DPCG Neoadj. FOLFIRINOX(8) Neoadj.
gemcitabine-based
CRT(3) + adj.
gemcitabine(4)
OS 06-2018 Recruiting
ALLIANCE A021806 344 Resectable <180◦ venous, patent
confluence, no arterial
Periop. mFOLFIRINOX (8 +
4)
Surgery + adj.
mFOLFIRINOX (12)
OS 2020 Start
recruiting
2020
Non-randomized studies
Lacy et al., Yale
NCT02047474
46 Resectable No venous
occlusion/encasement,
no arterial
Periop. mFOLFIRINOX (6 +
6)
– PFS at 1-yr 09-2013 Recruiting
IUCRO-0473
NCT02178709
48 Resectable NR Neoadj. FOLFIRINOX(4) – Pathological
complete
response*
04-2014 Recruiting
B. NEOADJUVANT REGIMENS OTHER THAN FOLFIRINOX
Randomized trials
UVA-PC-PD101
NCT02305186
56 (B)RPC NR Neoadj. pembrolizumab +
capecitabine-based CRT
Neoadj.
capecitabine-based
CRT
Toxicity, TILs 03-2015 Recruiting
Laheru et al.
Johns Hopkins
NCT00727441
87 Resectable No contact SMA/CA,
patent SMV/PV
Periop. GVAX(1+5) +
neoadj. cyclophosphamide
iv (a) or oral (b) + adj. CRT
c. Periop.
GVAX(1+5) + adj.
CRT
Safety, feasibility,
immune response
03-2015 Final results
pending
NEONAX NCT02047513 166 Resectable No arterial contact Periop. gemcitabine/nab-
paclitaxel(2+4)
Surgery + adj.
gemcitabine/nab-
paclitaxel(6)
DFS 04-2015 Recruiting
(Continued)
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TABLE 4 | Continued
Trial Sample
size
Stage Criteria Treatment regimen
(cycles)
Comparator
(cycles)
Primary
outcome
Start Status**
Non-randomized studies
Park et al.
National Cancer Center
Korea
NCT01333124
64 Resectable NR Neoadj. gemcitabine-based
CRT
– R0 resection rate 04-2014 Recruiting
Okada et al.
WakayamaNCT02926183
60 BRPC NCCN Neoadj. gemcitabine/nab-
paclitaxel(2)
– OS 10-2016 Recruiting
PRO30720
NCT03322995
125 (B)RPC NR Adaptive modification of
neoadj. treatment based on
clinical response + CRT***
– Completion
neoadj. regimen
incl. resection
06-2018 Recruiting
ESR-16-12315
NCT03572400
71 (B)RPC Stage I or II AJCC 8th Neoadj.
gemcitabine/dervalumab-
based CRT(6) + adj.
gemcitabine/dervalumab(6)
+ dervalumab(12 mo)
– DFS 11-2018 Recruiting
(B)RPC, (borderline) resectable pancreatic cancer; BRPC, borderline resectable pancreatic cancer; NCCN, National Comprehensive Cancer Network; AJCC, American Joint Committee
on Cancer; NR, not reported; DFS, disease-free survival; OS, overall survival; Neoadj., neoadjuvant; Adj., adjuvant; Periop., perioperative; CRT, chemoradiotherapy; IORT, intraoperative
radiation therapy; SBRT, stereotactic body radiation therapy; FOLFIRINOX, folinic acid + irinotecan + oxaliplatin + leucovorin; mFOLFIRINOX, modified FOLFIRINOX; FOLFOX6, folinic
acid + leucovorin + oxaliplatin; mLV5FU, modified folicin acid + leucovorin; PV, portal vein; SMA, superior mesenteric artery; CA, celiac artery; Incl., including; mo, months; Vs.,
versus; RCT, randomized controlled trial; TIL, tumor-infiltrating lymphocytes. *Evaluated by MRI or CT. **Based on clinicaltrials.gov, assessed on 21-08-2019. ***Adaptive modification of
neoadjuvant therapy: after 2 months, first-line chemotherapy is continued in responders, changed to second-line therapy in patients with stable disease, or changed to chemoradiation
in patients with local disease progression. After 4 months of chemotherapy, patients will be treated with chemoradiotherapy. Patients who underwent a resection after receiving <4
months of neoadjuvant chemotherapy, will be offered adjuvant therapy at the discretion of their physician.
aspects of neoadjuvant treatment regimens in patients with
(B)RPC. Table 4A presents selected ongoing trials including
neoadjuvant FOLFIRINOX, and Table 4B shows ongoing trials
for neoadjuvant regimens other than FOLFIRINOX.
Of the nine RCTs, two originate from France: the PANDAS-
PRODIGE44 trial for BRPC patients, and the PANACHE01-
PRODIGE48 trial for resectable PDAC. In the PANDAS-
PRODIGE44 trial, 90 BRPC patients will receive neoadjuvant
mFOLFIRINOX with (arm A) or without capecitabine-based
chemoradiotherapy (arm B), both followed by surgery and
adjuvant gemcitabine or modified LV5FU (NCT02676349).
This study uses R0 resection rate as primary endpoint. The
PANACHE01-PRODIGE48 is a three-arm trial with 2:2:1
allocation to 4 cycles of neoadjuvant mFOLFIRINOX (arm A)
or FOLFOX (arm B), both followed by 8 cycles of adjuvant
chemotherapy, or upfront surgery followed by 12 cycles of
adjuvant chemotherapy (arm C) (NCT02959879) (61). The
choice of adjuvant chemotherapy regimen will be left to the
medical teams, according to guidelines during the recruitment
period. The trial will include 160 resectable PDAC patients,
and the primary endpoint is 1-year OS. The SWOG S1505
trial is a randomized phase II study for patients with resectable
PDAC designed to determine the most promising perioperative
regimen for a larger phase III trial (NCT02562716). This study
has completed accrual and randomized 147 patients to either 3
cycles of perioperative mFOLFIRINOX (arm A) or perioperative
gemcitabine with nab-paclitaxel (arm B). The primary outcome
is 2-year OS, and results are anticipated in 2020. The ALLIANCE
A021501 was initially designed to evaluate the additional
value of hypofractionated radiation therapy to systemic therapy
as neoadjuvant treatment for BRPC of the pancreatic head,
with 18-month OS rate as primary outcome(NCT02839343).
(62) The initial design of this study was to randomize 134
patients to receive 8 cycles of mFOLFIRINOX (arm A), or 7
cycles of mFOLFIRINOX followed by either hypofractionated
stereotactic body radiation therapy (SBRT, 33Gy in 5 fractions)
or hypofractionated image guided radiation therapy (HIGRT,
25Gy in 5 fractions) (arm B). Following surgery, all patients
were scheduled for 4 cycles of adjuvant modified FOLFOX6
(mFOLFOX6). However, an interim analysis of the R0 resection
rate was conducted after accrual of 30 patients, after which
the radiotherapy arm (B) was suspended due to futility. The
NorPACT-1 trial is a multicenter trial for patients with resectable
PDAC of the pancreatic head, in which patients are randomized
in a 3:2 ratio to receive 4 cycles of neoadjuvant FOLFIRINOX
and adjuvant 4 cycles of gemcitabine-capecitabine (arm A), or
upfront surgery followed by 6 cycles of adjuvant gemcitabine-
capecitabine (arm B) (NCT02919787) (63). The sample size is
90 patients, and the primary endpoint is 1-year OS for those
patients who ultimately undergo a resection. The PREOPANC-
2 trial is a multicenter study performed by the Dutch Pancreatic
Cancer Group (DPCG) (NTR7292) (64). In this study, 368
(B)RPC patients will be randomized to receive 8 cycles of
neoadjuvant FOLFIRINOX (arm A) or 3 cycles of neoadjuvant
gemcitabine-based chemoradiotherapy with adjuvant 4 cycles of
gemcitabine, with median OS as primary endpoint. Last, the
ALLIANCE A021806 trial will compare 8 cycles of neoadjuvant
and 4 cycles of adjuvant mFOLFIRINOX to all 12 cycles
adjuvant mFOLFIRINOX for resectable PDAC. This trial will
start recruiting patients by the beginning of 2020 and will
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include 344 patients using median OS as primary endpoint. The
remaining three studies investigate neoadjuvant FOLFIRINOX
with a sample size of <50 patients, thereby limiting potential
impact on future guidelines [NCT02047474, NCT02178709,
NCT02172976 (NEPAFOX)].
Ongoing Neoadjuvant Trials—Regimens
Other Than FOLFIRINOX (Phase II and III)
At least three ongoing randomized phase II-III trials
(NCT02305186, NCT00727441, NCT02047513) and
four ongoing single-arm phase II trials are investigating
neoadjuvant regimens other than FOLFIRINOX (NCT01333124,
NCT02926183, NCT03322995, NCT03572400) (Table 4B).
The three-arm trial from Johns Hopkins aims to study the
feasibility and toxicity of perioperative GVAX vaccine therapy
± cyclophosphamide (oral or intravenous) in addition to
standard adjuvant chemoradiotherapy for resectable PDAC
(NCT00727441). This study is awaiting final results. In the
randomized NEONAX trial, 166 patients with resectable PDAC
are randomized to receive 6 cycles of gemcitabine with nab-
paclitaxel perioperative (2 neoadjuvant, 4 adjuvant) (arm A),
or all cycles adjuvant (arm B) (65). In the PRO30720 study, the
neoadjuvant regimen depends on the response on CT or MRI
scan, tumor marker levels, and performance status assessment
(NCT03322995). Sample size is 125 (B)RPC patients, who
will all start with 2 months of neoadjuvant chemotherapy.
Subsequent treatment depends on the response and may
include a therapy switch to an alternative chemotherapy
regimen or chemoradiotherapy. With this adaptive design,
the feasibility of personalized treatment will be evaluated.
The other ongoing trials comprise a variety of interventions
including chemoradiotherapy (NCT02305186, NCT01333124,
doublet chemotherapy (NCT02926183), and a combination of
chemotherapy and immunotherapy (NCT03572400).
Most ongoing studies of both neoadjuvant FOLFIRINOX
and other neoadjuvant regimens are underpowered to detect
a clinically relevant difference (e.g., 3 or 6 months) in OS.
Some studies are hypothesis-generating in their selection of
intermediate outcome, such as R0 resection or treatment
completion rates. Other studies do have survival as primary
outcome, but have a sample size that is too small to detect
a clinically relevant survival difference of 3 or 6 months.
Assuming an alpha error of 0.05 and a power of 80%, a sample
size exceeding 300 patients is needed to detect a difference
in median OS of 6 months. An explanation for inadequate
sample size is often a concern for feasibility. The PREOPANC-
2 trial appears to be the only RCT that may be adequately
powered to assess whether neoadjuvant FOLFIRINOX is superior
to other regimens. Furthermore, the ALLIANCE A021806 is
the only adequately powered RCT comparing perioperative (8
+ 4 cycles) mFOLFIRINOX with adjuvant mFOLFIRINOX
(12 cycles).
CONCLUSION
Selection bias hampers comparing survival outcomes between
neoadjuvant and adjuvant trials. Patients in neoadjuvant trials
may have occult metastatic disease at surgery or may not fully
recover from surgery; patients in adjuvant trials were selected
after overcoming these hurdles. Only a direct comparison in
an RCT will avoid this inevitable selection bias. Despite the
limited number of published RCTs comparing a neoadjuvant
approach to upfront surgery, patients with resectabel PDAC and
BRPC seem to consistently benefit from a neoadjuvant approach
with regards to the R0 resection rate. Furthermore, the DFS
and OS were at least equal or superior with a neoadjuvant
approach compared to upfront surgery. The currently published
RCTs supporting neoadjuvant treatment over upfront resection
included mostly single-agent based regimens. The multi-agent
regimen FOLFIRINOX has considerable toxicity requiring a
good performance status. FOLFIRINOX has already proven
superior to gemcitabine in the metastatic and adjuvant setting.
Ongoing RCTs will investigate whether FOLFIRINOX is indeed
the superior regimen in the neoadjuvant setting. Likely,
neoadjuvant FOLFIRINOX may further improve the outcomes
of this vulnerable patient group. In addition, future RCTs should
study the optimal number of neoadjuvant cycles, the value of
additional neoadjuvant chemoradiotherapy, the optimal patient
selection for surgical resection, and the need for subsequent
adjuvant chemotherapy. For patients with a good performance
status, we advocate patient participation in one of the large
ongoing RCTs evaluating the potential benefit of neoadjuvant
FOLFIRINOX for (B)RPC patients.
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